U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830199) titled 'A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics' on Sept. 15.
Brief Summary: The study is being conducted to evaluate the safety and tolerability of SHR-4595 for injection in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical studies (RP2D) of SHR-4595.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
DRUG: SHR-4595 for Injection
SHR-4595 for injection, in different doses.
Recruitment ...